MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, marking a significant step in commercializing voice-based impairment detection technology for workplace safety. The kiosks utilize artificial intelligence to analyze short voice samples, detecting over 140 acoustic markers associated with alcohol, drug, or fatigue-related impairment. The AI models have been trained on more than 50 million data points, aiming to provide high accuracy in predicting intoxication.
The prototypes are now entering testing, validation, and data-analysis phases, involving industry participants, speech specialists, and software engineers. This process is intended to refine predictive models and assess real-world performance. MindBio is targeting safety-sensitive industries such as mining, aviation, construction, transportation, and law enforcement, where large workforces and operational risks make conventional testing methods—like breath, saliva, urine, and laboratory tests—costly and time-consuming.
The company's approach offers rapid, scalable, and less invasive initial screening. Individuals flagged for potential impairment can undergo additional evaluation using established testing protocols. This two-step process aims to enhance workplace safety while reducing the burden of frequent testing. The technology's edge computing capability allows for on-site processing, ensuring data privacy and low latency.
MindBio's AI prediction model has demonstrated remarkable accuracy in predicting alcohol intoxication using voice alone. The enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for detection in various environments. The company is focusing on industries where impairment can have severe consequences, and where traditional testing may be impractical.
According to the company, the kiosks are designed to be user-friendly and can provide results within seconds. This could streamline safety protocols in high-risk workplaces. The validation phase will be crucial in determining the system's reliability and potential for widespread adoption.
For more information, visit the company's website at www.MindBioTherapeutics.com. The latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF.
